1
|
Kluczna A, Orzeł R, Bardowska A, Dzierżanowski T. The Degree of Acceptance of Cocoon Strategy of Vaccination against Influenza and COVID-19 in Palliative Home Care Professionals and Caregivers. Vaccines (Basel) 2023; 11:1235. [PMID: 37515049 PMCID: PMC10383800 DOI: 10.3390/vaccines11071235] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2023] [Revised: 07/02/2023] [Accepted: 07/11/2023] [Indexed: 07/30/2023] Open
Abstract
Palliative care patients are an immunocompromised population, so the cocooning strategy of vaccinating those around them is a suitable protective strategy against infections. This is especially significant for infectious diseases such as influenza and COVID-19, which pose a challenge to the healthcare system. In order to improve the patient's quality of life, it is necessary to develop research-based, defined strategies. This questionnaire-based study was conducted to determine the level of knowledge about influenza and SARS-CoV-2 coronavirus vaccination among the factual caregivers and medical staff in the palliative care setting. The survey revealed that the sources of knowledge about vaccination varied and depended on one's role. Doctors and nurses used professional literature, while other medical professionals relied on the Internet, mass media, and information from family and friends. The study also showed that adherence to vaccination guidelines was not associated with COVID-19 incidence. The overall opinion on vaccination was positive, but the degree of acceptance varied by the role. Palliative care nurses and caregivers were the groups that were the least accepting of vaccination. To improve the acceptance of vaccinations, a remedial program based on professional education should be implemented using the sources declared by the respondents. It may help improve the quality of life for palliative care patients and prevent the spread of infectious diseases.
Collapse
Affiliation(s)
- Agnieszka Kluczna
- Department of Palliative Medicine, Institute of Sciences, University of Opole, 45-052 Opole, Poland
| | - Rafał Orzeł
- Laboratory of Palliative Medicine, Department of Social Medicine and Public Health, Medical University of Warsaw, 02-007 Warsaw, Poland
| | - Anna Bardowska
- Laboratory of Palliative Medicine, Department of Social Medicine and Public Health, Medical University of Warsaw, 02-007 Warsaw, Poland
| | - Tomasz Dzierżanowski
- Laboratory of Palliative Medicine, Department of Social Medicine and Public Health, Medical University of Warsaw, 02-007 Warsaw, Poland
| |
Collapse
|
2
|
Vaillant V, Tretiakova I, Berthold D, Scheer M, Kimmig A, Hagenguth A, Kaestner J, Meinhardt A, Kriwy P, Wolff J, Hauch H. Vaccine Preventable Diseases in Pediatric Palliative Care - A Multicenter Cross-Sectional Study. J Pain Symptom Manage 2023; 65:101-110. [PMID: 36334849 DOI: 10.1016/j.jpainsymman.2022.10.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2022] [Revised: 10/20/2022] [Accepted: 10/25/2022] [Indexed: 11/07/2022]
Abstract
CONTEXT Vaccine preventable diseases lead to distressful symptoms and complications among pediatric patients receiving specialized home palliative care. There was no data on the vaccination compliance. OBJECTIVES The objective was to determine the vaccination coverage, discuss the relevance of vaccinations and provide vaccination recommendations in pediatric palliative care. METHODS Vaccination data were compared in a multicenter cross-sectional study. Expert interviews were conducted to evaluate symptom burden. The vaccination status of patients treated by six German pediatric specialized home palliative care teams was recorded from January 2019 to December 2019. The data were compared to the national immunization schedule and the vaccination rate of a representative German pediatric cohort. Onset of missed vaccination was compared to the date of diagnosis of the life-limiting condition. A risk score was calculated to evaluate the relevance of each individual vaccinations. RESULTS Vaccination rates of Tdpa, haemophilus influenzae type B, poliomyelitis, hepatitis B, pneumococcal disease, meningococcal diseases type C, and MMR were lower compared to healthy controls. There were no significant differences in varicella. In most cases the discontinuation of recommended immunizations occurred after diagnosis of the palliative condition. Influenza had the highest risk score and was the most frequent vaccine preventable disease in retrospective data. This paper includes a pragmatic proposal for the management of vaccination in this vulnerable population. CONCLUSION Children and adolescents with life-limiting conditions are at increased risk of vaccine preventable diseases. Individual vaccination counselling is recommended.
Collapse
Affiliation(s)
- Vera Vaillant
- University Hospital of Giessen and Marburg, Palliative Care Team for Children (V.V., A.M., H.H.), Giessen, Hesse, Germany.
| | - Irina Tretiakova
- Bad Hersfeld Hospital, Academic Children's Hospital (I.T.), Bad Hersfeld, Hesse, Germany
| | - Daniel Berthold
- Department of Clinical Oncology and Palliative Care (D.B.), University Hospital of Giessen and Marburg, Giessen, Hesse, Germany
| | - Mario Scheer
- Children's Hospice Service Syke, Palliative Care Team (M.S.), Syke, Lower Saxony, Germany
| | - Astrid Kimmig
- University Children's Hospital Tuebingen, Palliative Care Team for Children (A.K.), Tuebingen, Baden-Württemberg, Germany
| | - Andrea Hagenguth
- German Red Cross "Heinrich-Schwesternschaft e.V.", Palliative Care Team (A.H.), Kiel, Schleswig-Holstein, Germany
| | - Jens Kaestner
- University Hospital Jena, Palliative Care Team for Children (J.K.), Jena, Thuringia, Germany
| | - Andrea Meinhardt
- University Hospital of Giessen and Marburg, Palliative Care Team for Children (V.V., A.M., H.H.), Giessen, Hesse, Germany
| | - Peter Kriwy
- Chemnitz University of Technology (P.K.), Chemnitz, Saxony, Germany
| | | | - Holger Hauch
- University Hospital of Giessen and Marburg, Palliative Care Team for Children (V.V., A.M., H.H.), Giessen, Hesse, Germany
| |
Collapse
|
3
|
Coll PP, Costello VW, Kuchel GA, Bartley J, McElhaney JE. The Prevention of Infections in Older Adults: Vaccination. J Am Geriatr Soc 2019; 68:207-214. [PMID: 31613000 DOI: 10.1111/jgs.16205] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2019] [Revised: 09/04/2019] [Accepted: 09/05/2019] [Indexed: 12/13/2022]
Abstract
All living beings are at risk for experiencing infections; humans are no exception. The prestige and credibility of modern medicine is built in large part on achievements in preventing and treating infectious diseases. For most of human history, there was little that could be done to prevent and treat infections. Millions of humans, of all ages, have died from infections; and in some parts of the world, infection-related deaths remain common. Advances in preventing and treating infectious diseases include improved sanitization, sterilization, pasteurization, immunization, and antibiotics. Vaccination has played a major role in the prevention of lethal diseases, such as smallpox, diphtheria, cholera, and influenza. Because of developing or waning immune function, the young and the old are at particularly high risk of experiencing infections. Influenza and pneumonia remain common causes of death in older adults. Influenza, in particular, has the potential to result in premature mortality for all age groups, including those who are older and particularly those who live in congregate settings. Vaccination is important in promoting healthy aging. J Am Geriatr Soc 68:207-214, 2019.
Collapse
Affiliation(s)
- Patrick P Coll
- Department of Family Medicine and Center on Aging, University of Connecticut Health Center, Farmington, Connecticut
| | - Victoria W Costello
- Center on Aging, University of Connecticut Health Center, Farmington, Connecticut
| | - George A Kuchel
- Center on Aging, University of Connecticut Health Center, Farmington, Connecticut
| | - Jenna Bartley
- Center on Aging, University of Connecticut Health Center, Farmington, Connecticut
| | | |
Collapse
|
4
|
Haugh M, Gresset-Bourgeois V, Macabeo B, Woods A, Samson SI. A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries. Expert Rev Vaccines 2017; 16:545-564. [PMID: 28460594 DOI: 10.1080/14760584.2017.1324302] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
INTRODUCTION Vaxigrip, a trivalent split-virion, inactivated vaccine available since 1968 has been in use longer than any other influenza vaccine. It is the most widely-used influenza vaccine, with more than 1.8 billion doses distributed in more than 120 countries. Areas covered: The significant body of evidence that confirms the efficacy, effectiveness, immunogenicity, and safety of Vaxigrip in healthy individuals of all ages and at-risk populations is summarized. The results from at least 15 randomized efficacy trials and 15 other studies have demonstrated that vaccination with Vaxigrip is efficacious against various clinical endpoints. It was estimated that more than 37 million laboratory-confirmed influenza episodes, 476,000 influenza-related hospitalizations, and 67,000 influenza-related deaths have been avoided by the more than 1.8 billion doses of Vaxigrip that have been distributed, emphasizing its important public health impact. Expert commentary: This strong evidence base in favor of Vaxigrip provides a robust foundation to support the implementation of the quadrivalent formulation. This quadrivalent formulation of Vaxigrip contains two A and two B influenza strains (VaxigripTetra), and has a similar immunogenicity and safety profile to the trivalent formulation while offering broader protection due to the addition of the second influenza B strain.
Collapse
Affiliation(s)
| | - Viviane Gresset-Bourgeois
- b Department of Medical Affairs, Value and Access and Pharmacovigilance , Sanofi Pasteur , Lyon cedex 07 , France
| | - Bérengère Macabeo
- b Department of Medical Affairs, Value and Access and Pharmacovigilance , Sanofi Pasteur , Lyon cedex 07 , France
| | - Anne Woods
- b Department of Medical Affairs, Value and Access and Pharmacovigilance , Sanofi Pasteur , Lyon cedex 07 , France
| | - Sandrine I Samson
- b Department of Medical Affairs, Value and Access and Pharmacovigilance , Sanofi Pasteur , Lyon cedex 07 , France
| |
Collapse
|
5
|
Poeppl W, Lagler H, Raderer M, Sperr WR, Zielinski C, Herkner H, Burgmann H. Influenza vaccination perception and coverage among patients with malignant disease. Vaccine 2015; 33:1682-7. [DOI: 10.1016/j.vaccine.2015.02.029] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2014] [Revised: 12/10/2014] [Accepted: 02/12/2015] [Indexed: 11/26/2022]
|